GlassScriptPhysician profile
Jennifer Murdock
NPI 1538401583
$316,376.52
in general payments reported to CMS, 2019-2025
16 companies · $3,243 in 2025
The $3,243 reported for 2025 was more than what 85% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $21K · 2021: $30K · 2022: $115K · 2023: $142K · 2024: $4,852 · 2025: $3,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $116K · Travel and Lodging: $20K · Food and Beverage: $8,847 · Consulting Fee: $4,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $116,425.00 |
| Travel and Lodging | $19,866.20 |
| Food and Beverage | $8,846.75 |
| Consulting Fee | $4,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $306,160.04 | 2020-2023 | Tepezza |
| Galderma Laboratories, L.P. | $6,517.04 | 2019-2025 | Dysport |
| Abbvie INC. | $1,886.00 | 2023-2025 | |
| Allergan, INC. | $465.66 | 2019-2022 | |
| Revance Therapeutics, INC. | $350.15 | 2024-2025 | Daxxify |
| Tarsus Pharmaceuticals, INC. | $265.82 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $196.60 | 2022-2024 | Cequa |
| Harrow Eye, LLC | $130.49 | 2025 | Vevye |
| Alcon Vision LLC | $124.99 | 2025 | Tryptyr |
| Oyster Point Pharma, INC. | $90.76 | 2024 | Tyrvaya |
| Ibsa Pharma INC. | $49.33 | 2019 | |
| Tearlab Corp | $41.94 | 2023 | Tearlab Osmolarity System |
| Alexion Pharmaceuticals, INC. | $25.24 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.60 | 2024 | Purified Cortrophin Gel |
| Medical Device Business Services, INC. | $24.17 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.69 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Murdock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.